tetano
Editor, Senior Moderator
Sci Rep
. 2024 Jul 23;14(1):16876.
doi: 10.1038/s41598-024-67028-3. A randomised controlled trial of plasma exchange compared to standard of care in the treatment of severe COVID-19 infection (COVIPLEX)
Nishkantha Arulkumaran[SUP] 1 2 [/SUP], Mari Thomas[SUP] 3 4 [/SUP], Matthew Stubbs[SUP] 4 [/SUP], Nithya Prasanna[SUP] 4 [/SUP], Maryam Subhan[SUP] 4 [/SUP], Deepak Singh[SUP] 5 [/SUP], Gareth Ambler[SUP] 6 [/SUP], Alessia Waller[SUP] 1 2 [/SUP], Mervyn Singer[SUP] 1 2 [/SUP], David Brealey[SUP] 1 2 [/SUP], Marie Scully[SUP] 7 8 [/SUP]
Affiliations
COVID-19 disease is associated with a hyperinflammatory, pro-thrombotic state and a high mortality. Our primary objective was to assess the change in inflammatory and thrombotic markers associated with PEX, and secondary objectives were to assess the effects of PEX on progression of respiratory failure and incidence of acute thrombotic events. We conducted a prospective, phase II, non-blinded randomised control trial of plasma exchange compared to standard of care in critically ill adults with severe COVID-19 associated respiratory failure, requiring supplemental oxygen or ventilatory support and elevated thrombo-inflammatory markers (LDH, CRP, ferritin, and D-Dimer). Patients randomised to receive PEX were treated with a daily single volume plasma exchange for a minimum of five days. Twenty-two patients were randomised of who 11 received PEX. Demographic and clinical characteristics were similar between groups at presentation. PEX was associated with a significant reduction in pro-thrombotic markers FVIII, VWF and VWF Ag: ADAMTS 13 ratio (p < 0.001). There were no differences in the reduction of inflammatory markers, severity of respiratory failure (p = 0.7), thrombotic events (p = 0.67), or mortality (p > 0.99) at 28 days. PEX successfully reduced pro-thrombotic markers, although was not associated with reduction in inflammatory markers, respiratory failure, or thrombotic events.Trial registration: (NCT04623255); first posted on 10/11/2020.
. 2024 Jul 23;14(1):16876.
doi: 10.1038/s41598-024-67028-3. A randomised controlled trial of plasma exchange compared to standard of care in the treatment of severe COVID-19 infection (COVIPLEX)
Nishkantha Arulkumaran[SUP] 1 2 [/SUP], Mari Thomas[SUP] 3 4 [/SUP], Matthew Stubbs[SUP] 4 [/SUP], Nithya Prasanna[SUP] 4 [/SUP], Maryam Subhan[SUP] 4 [/SUP], Deepak Singh[SUP] 5 [/SUP], Gareth Ambler[SUP] 6 [/SUP], Alessia Waller[SUP] 1 2 [/SUP], Mervyn Singer[SUP] 1 2 [/SUP], David Brealey[SUP] 1 2 [/SUP], Marie Scully[SUP] 7 8 [/SUP]
Affiliations
- PMID: 39043682
- PMCID: PMC11266620
- DOI: 10.1038/s41598-024-67028-3
COVID-19 disease is associated with a hyperinflammatory, pro-thrombotic state and a high mortality. Our primary objective was to assess the change in inflammatory and thrombotic markers associated with PEX, and secondary objectives were to assess the effects of PEX on progression of respiratory failure and incidence of acute thrombotic events. We conducted a prospective, phase II, non-blinded randomised control trial of plasma exchange compared to standard of care in critically ill adults with severe COVID-19 associated respiratory failure, requiring supplemental oxygen or ventilatory support and elevated thrombo-inflammatory markers (LDH, CRP, ferritin, and D-Dimer). Patients randomised to receive PEX were treated with a daily single volume plasma exchange for a minimum of five days. Twenty-two patients were randomised of who 11 received PEX. Demographic and clinical characteristics were similar between groups at presentation. PEX was associated with a significant reduction in pro-thrombotic markers FVIII, VWF and VWF Ag: ADAMTS 13 ratio (p < 0.001). There were no differences in the reduction of inflammatory markers, severity of respiratory failure (p = 0.7), thrombotic events (p = 0.67), or mortality (p > 0.99) at 28 days. PEX successfully reduced pro-thrombotic markers, although was not associated with reduction in inflammatory markers, respiratory failure, or thrombotic events.Trial registration: (NCT04623255); first posted on 10/11/2020.